A recent trial suggests that canagliflozin may preserve kidney function in type 2 diabetes patients by safeguarding podocytes, offering new insights into its protective mechanisms beyond glycaemic control.
Canagliflozin may do more than lower blood sugar in diabetic kidney disease, according to a randomised trial published in Annals of the Academy of Medicine, Singapore. The study found that the drug improved measures of kidney damage over 12 weeks while also showing signals that point to protection of podocytes, the specialised cells that help keep protein in the bloodstream and out of the urine.
The trial enrolled 180 adults with type 2 diabetes and diabetic kidney disease at Shangyu People’s Hospital in China and randomised them to canagliflozin plus standard care or placebo plus standard care. After exclusions and follow-up losses, 87 patients in the canagliflozin arm and 85 in the control arm completed the study. Investigators and outcome assessors were blinded, and both groups received similar background treatment, including glucose-lowering therapy, statins and stable ACE inhibitor or angiotensin receptor blocker use where appropriate.
Blood sugar improved in both groups, but the differences between them were not significant, suggesting that the kidney findings were not simply a result of better glucose control. By week 12, the canagliflozin group had lower blood urea nitrogen, urinary protein excretion and urinary albumin-to-creatinine ratio than the control group. It also had fewer urinary podocytes and lower urinary podocalyxin-to-creatinine ratios, which the researchers used as a marker of podocyte injury.
The most notable part of the analysis was the mediation model. The authors reported that changes in urinary podocalyxin appeared to explain most of the drug’s effect on albuminuria and 24-hour urinary protein, while the effect on serum creatinine seemed to involve both podocyte protection and other pathways. The paper is careful to note that this kind of analysis shows statistical mediation, not proof of cause and effect.
Safety outcomes were reassuring. The rate of adverse events was low and similar in both groups, with no significant increase in genitourinary infection, hypoglycaemia, hypotension or clinically meaningful weight loss among patients taking canagliflozin.
The findings add to a growing body of evidence that sodium-glucose cotransporter 2 inhibitors may protect the kidney through mechanisms beyond glucose lowering. The Annals paper points to podocyte preservation as one plausible route, echoing earlier experimental and clinical work suggesting that these drugs can reduce protein leakage and slow kidney injury in diabetes. Still, the trial was small, single-centre and short, so it cannot answer whether the benefit lasts or translates into fewer cases of kidney failure over time.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
